Form 4: Oncolytics Biotech CEO Granted Stock Options

Jared Kelly, CEO of Oncolytics Biotech, received stock options for 755,000 shares with an exercise price of $1.06, vesting over three years.

Summary

• Jared Kelly, Chief Executive Officer and Director of Oncolytics Biotech Inc., was granted stock options on June 1, 2026.
• The options are for 755,000 common shares with an exercise price of $1.06 per share.
• The exercise price is equivalent to the closing price of the company's common stock on the Nasdaq Capital Market on the grant date.
• These stock options will vest in three equal annual installments, starting on June 1, 2027.
• Vesting is contingent upon Kelly's continued service or employment with the company on each respective vesting date.
• The options have an expiration date of June 1, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard executive compensation event rather than a significant operational or financial development.

Positives

• Grant of stock options to the CEO signals management's commitment and alignment with shareholder interests.
• The exercise price being set at the market price on the grant date suggests a standard incentive practice.
• A three-year vesting schedule encourages long-term retention and performance.

Negatives

• The filing does not contain any negative financial or operational information.

Risks

• The value of the stock options is directly tied to the future performance of Oncolytics Biotech's stock price.
• If the company's stock price does not appreciate significantly above the $1.06 exercise price, the options may not be exercised.
• Continued service is a condition for vesting, meaning any departure before vesting dates could result in forfeiture of unvested options.

Future Outlook

The future outlook for the stock options is dependent on the company's stock performance and the continued service of Jared Kelly. The options are exercisable until June 1, 2036, providing a long-term incentive.

Management Comments

• The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Capital Market on the date of grant, June 1, 2026.
• The stock option vests in three equal annual installments with the first tranche vesting on June 1, 2027, subject to the Reporting Person's continued service or employment, as applicable, on each such vesting date.

Industry Context

StockSavvy.ai notes that the granting of stock options to senior executives, particularly the CEO, is a common practice in the biotechnology sector to incentivize performance and align executive interests with those of shareholders, especially given the inherent volatility and long development cycles in the industry.

Stakeholder Impact

• Shareholders: The grant of options aligns management's incentives with stock performance, potentially benefiting shareholders if the stock price increases.
• Employees: The vesting schedule tied to continued service reinforces employee retention, which can be crucial for operational stability.
• Management: Jared Kelly receives a performance-based incentive tied to the company's success.

Next Steps

• Jared Kelly will continue his service or employment with Oncolytics Biotech to meet vesting requirements.
• The stock options will become exercisable in tranches over three years, starting June 1, 2027.
• The options can be exercised by the holder up to their expiration date on June 1, 2036.

Key Dates

Keywords

Oncolytics Biotech, ONCY, Form 4, Stock Options, Executive Compensation, Insider Trading, SEC Filing, Jared Kelly, Grant Date, Vesting Schedule